|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Diabetic Neuropathies | |||||
| 2 | More general conditions related to this trial | ||||
| Diabetes Complications | |||||
| Diabetes Mellitus | |||||
| Endocrine System Diseases | |||||
| Nervous System Diseases | |||||
| Neuromuscular Diseases | |||||
| Peripheral Nervous System Diseases | |||||
| 3 | Interventions listed in this trial | ||||
| Duloxetine hydrochloride | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Duloxetine | |||||
| 5 | More general drug interventions related to this trial | ||||
| Adrenergic Agents | |||||
| Adrenergic Uptake Inhibitors | |||||
| Antidepressive Agents | |||||
| Central Nervous System Agents | |||||
| Dopamine Agents | |||||
| Dopamine Uptake Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Neurotransmitter Uptake Inhibitors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Psychotropic Drugs | |||||
| Serotonin Agents | |||||
| Serotonin Uptake Inhibitors | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| Eli Lilly and Company | |||||
| Shionogi | |||||